Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Cash & Equivalents (2021 - 2025)

LifeStance Health (LFST) has disclosed Cash & Equivalents for 5 consecutive years, with $175.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 13.55% to $175.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $175.5 million through Dec 2025, up 13.55% year-over-year, with the annual reading at $175.5 million for FY2025, 13.55% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $175.5 million at LifeStance Health, up from $141.8 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $276.2 million in Q2 2021, with the low at $32.4 million in Q1 2024.
  • Average Cash & Equivalents over 5 years is $118.1 million, with a median of $108.6 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents crashed 64.99% in 2022, then skyrocketed 314.62% in 2025.
  • Over 5 years, Cash & Equivalents stood at $148.0 million in 2021, then dropped by 26.62% to $108.6 million in 2022, then dropped by 27.43% to $78.8 million in 2023, then surged by 96.1% to $154.6 million in 2024, then increased by 13.55% to $175.5 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $175.5 million, $141.8 million, and $129.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.